More than 150 GlaxoSmithKline (GSK) employees and Duke faculty and students attended the second Joint GSK-Duke Workshop on Critical Statistical Issues for Drug Development, held at Duke in the Hock Plaza building-home of the Duke Department of Biostatistics and Bioinformatics-September 30. The program led with a keynote address, "Innovation and Statistics in Clinical Trials," by Greg Campbell, director of the Division of Biostatistics in Center for Devices and Radiological Health at the U.S. Food and Drug Administration. It was followed by six sessions that offered 18 presentations on Bayesian priors, genetics, benefit-risk, bio-marker oncology trials, novel Bayesian approaches, and adaptive trials, in addition to a poster session and Q&A panel.
展开▼
